Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Polymer-semaxanib moiety conjugates
US9943605B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9943605-B2 |
| Application number | US-201113995301-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 23, 2011 |
| Priority date | Dec 23, 2010 |
| Publication date | Apr 17, 2018 |
| Grant date | Apr 17, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound encompassed by the formula: and pharmaceutically acceptable salts thereof, wherein n is from 3 to 10. 2. A composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient. 3. A composition of matter comprising a compound of claim 1 , wherein the compound is present in a dosage form. 4. The compound of claim 1 , wherein n is from 3 to 9. 5. The compound of claim 1 , wherein n is 3. 6. The compound of claim 1 , wherein n is 4. 7. The compound of claim 1 , wherein n is 5. 8. The compound of claim 1 , wherein n is 6. 9. The compound of claim 1 , wherein n is 7. 10. The compound of claim 1 , wherein n is 8. 11. The compound of claim 1 , wherein n is 9.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Indoles, e.g. pindolol · CPC title
- A61K47/60Primary
the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title
in position 2 · CPC title
- A61K47/545Primary
Heterocyclic compounds (A61K47/558 takes precedence) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9943605B2 cover?
- The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
- Who is the assignee on this patent?
- Riggs Sauthier Jennifer, Allums Donald Stephanie, Culbertson Sean M, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K47/60. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).